Salute e Benessere
Beactica conducts first advisory meeting with the Swedish Medical Products Agency regarding the development of BEA-17
BEA-17 is a first-in-class small molecule targeted degrader of lysine demethylase 1 (LSD1) and its co-factor CoREST. In syngeneic animal models of cancer, the compound has shown promising potentiation of immune-modulating treatments in several cancer forms, including anti-PD1 checkpoint inhibitors in colon cancer (CT26) and standard of care (temozolomide and radiation) in glioblastoma (GL261). Pharmacokinetic studies of BEA-17 show good blood-brain-barrier penetration and oral availability. BEA-17 is investigational and not approved anywhere globally. Its efficacy and safety in humans have not been established. BEA-17 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM).
Beactica Therapeutics AB is a privately held precision medicine company with a pipeline of novel small molecule therapeutics aimed at treating diseases with significant unmet medical need. Beactica's approach is centered around the Eclipsor™ platform that enables the efficient development of allosteric modulators and targeted protein degraders. Beactica deliver value to patients and shareholders by advancing its programmes to clinical proof of concept. For more information, please visit www.beactica.com.
Per Källblad
CEO
per.kallblad@beactica.com
Tel: +46 18 56 08 80
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/beactica-therapeutics-ab/r/beactica-conducts-first-advisory-meeting-with-the-swedish-medical-products-agency-regarding-the-deve,c4246219
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/beactica-conducts-first-advisory-meeting-with-the-swedish-medical-products-agency-regarding-the-development-of-bea-17-302576676.html